Evazarsen Sodium is an antisense oligonucleotide commercialized by Ionis Pharmaceuticals, with a leading Phase II program in Systolic Heart Failure. According to Globaldata, it is involved in 5 clinical trials, of which 3 were completed, and 2 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Evazarsen Sodium’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Evazarsen Sodium is expected to reach an annual total of $38 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Evazarsen Sodium Overview
IONIS-AGT-LRx is under development for treatment-resistant hypertension, mild hypertension and heart failure with reduced ejection fraction (systolic heart failure). It is administered through the subcutaneous route. It is an antisense oligonucleotide which acts by targeting angiotensinogen (AGT). It is developed based on ligand conjugation antisense (LICA) technology.
Ionis Pharmaceuticals Overview
Ionis Pharmaceuticals (Ionis), formerly ISIS Pharmaceuticals, Inc., focuses on the discovery and development of RNA-targeted drugs. The company develops medicines to treat various diseases including cancer, pulmonary, cardiovascular diseases, neurological and infectious diseases. Its major products include Spinraza for spinal muscular atrophy, Tegsedi for neuropathy and Waylivra for familial chylomicronemia syndrome. Ionis also has a pipeline of products in different phases of clinical trials. It develops products based on its proprietary antisense technology. The company partnered with other pharmaceutical companies to develop a range of products in different therapeutic areas. The company sells its products in North America and Europe. Ionis is headquartered in Carlsbad, California, the US.
The company reported revenues of (US Dollars) US$810.5 million for the fiscal year ended December 2021 (FY2021), an increase of 11.1% over FY2020. The operating loss of the company was US$38.8 million in FY2021, compared to an operating loss of US$172.1 million in FY2020. The net loss of the company was US$28.6 million in FY2021, compared to a net loss of US$444.3 million in FY2020. The company reported revenues of US$159.8 million for the third quarter ended September 2022, an increase of 19.4% over the previous quarter.
For a complete picture of Evazarsen Sodium’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.